</head> <body style="-ms-text-size-adjust:100%;-webkit-text-size-adjust:100%;margin:0;min-width:100%;padding:0;width:100%" data-bg-color="#e8e8e8" bgcolor="#e8e8e8">
#5c2e84 #4d4e4e {{custommediaemailsadvanced::eyebrow_copy}} {{custommediaemailsadvanced::eyebrow_background_color}} {{custommediaemailsadvanced::eyebrow_text_color}} {{custommediaemailsadvanced::is_partner_podcast}} Or listen on your favorite{nbs}platform: {{custommediaemailsadvanced::partner_podcast_spotify_url}} {{custommediaemailsadvanced::partner_podcast_apple_url}} {{custommediaemailsadvanced::partner_podcast_google_url}} /uploads/p_r_n_k_bro_v_et_artboard_79_2_x-27fa0106590d868ae3fcb8c49ff22af9.png {{custommediaemailsadvanced::logo_self_hosted}} 99 {{custommediaemailsadvanced::logo_height}} {{custommediaemailsadvanced::logo_padding}} {{custommediaemailsadvanced::logo_alt_text}} {{custommediaemailsadvanced::logo_url}} {{custommediaemailsadvanced::no_border_under_logo}} {{custommediaemailsadvanced::apply_logo_over_background_image}} true /uploads/p_r_n_k_bro_v_et_header_2_x-3e0fbee14497751ad7e2b73a91b4477c.jpg {{custommediaemailsadvanced::desktop_header_image_alt}} {{custommediaemailsadvanced::desktop_header_image_alt_1x}} true true {{custommediaemailsadvanced::mobile_header_image}} {{custommediaemailsadvanced::mobile_header_image_alt}} {{custommediaemailsadvanced::add_left_right_padding_to_header_image}} {{custommediaemailsadvanced::add_bottom_padding_to_header_image}} {{custommediaemailsadvanced::add_top_padding_to_header_image}} {{custommediaemailsadvanced::header_image_padding_background_color}} {{custommediaemailsadvanced::scale_mobile_header_image}} {{custommediaemailsadvanced::background_height}} #000000 {{custommediaemailsadvanced::headline_image}} {{custommediaemailsadvanced::headline_image_self_hosted}} {{custommediaemailsadvanced::headline_url}} 480 379 {{custommediaemailsadvanced::headline_image_custom_css}} {{custommediaemailsadvanced::place_headline_image_above_header_image}} {{custommediaemailsadvanced::place_headline_image_below_header_image}} {{custommediaemailsadvanced::spacer_image}} {{custommediaemailsadvanced::spacer_image_self_hosted}} 600 {{custommediaemailsadvanced::spacer_image_height}} {{custommediaemailsadvanced::spacer_image_scale_desktop_padding_bottom}} {{custommediaemailsadvanced::spacer_image_scale_mobile_padding_bottom}} {{custommediaemailsadvanced::subhead_copy}} {{custommediaemailsadvanced::large_subhead_copy}} {{custommediaemailsadvanced::subhead_td_custom_css}} {{custommediaemailsadvanced::subhead_span_custom_css}} {{custommediaemailsadvanced::horizontal_rule_under_subhead}} {{custommediaemailsadvanced::intro_copy}} {{custommediaemailsadvanced::intro_centered}} {{custommediaemailsadvanced::intro_copy_td_custom_css}} {{custommediaemailsadvanced::intro_copy_span_custom_css}} {{custommediaemailsadvanced::horizontal_rule_under_intro}}

Finding a safe and effective treatment protocol for dogs with seizures can often serve up a challenge for the veterinary practitioner. KBroVet®-CA1 is a conditionally approved, flavored, chewable tablet for the treatment of idiopathic epilepsy in dogs, with a proven safety record from the FDA. 

{{custommediaemailsadvanced::custom_body_text_color}} {{custommediaemailsadvanced::custom_body_background_color}} text-align: center; padding-top: 10px; {{custommediaemailsadvanced::body_span_custom_css}} {{custommediaemailsadvanced::custom_body_horizontal_rule_color}} {{custommediaemailsadvanced::ordered_list_bullet_1}} 1 {{custommediaemailsadvanced::custom_icon_1}} {{custommediaemailsadvanced::custom_icon_1_self_hosted}} {{custommediaemailsadvanced::custom_icon_1_width}} {{custommediaemailsadvanced::ordered_list_bullet_2}} 2 {{custommediaemailsadvanced::custom_icon_2}} {{custommediaemailsadvanced::custom_icon_2_self_hosted}} {{custommediaemailsadvanced::custom_icon_2_width}} {{custommediaemailsadvanced::ordered_list_bullet_3}} 3 {{custommediaemailsadvanced::custom_icon_3}} {{custommediaemailsadvanced::custom_icon_3_self_hosted}} {{custommediaemailsadvanced::custom_icon_3_width}} {{custommediaemailsadvanced::ordered_list_bullet_4}} 4 {{custommediaemailsadvanced::custom_icon_4}} {{custommediaemailsadvanced::custom_icon_4_self_hosted}} {{custommediaemailsadvanced::custom_icon_4_width}} {{custommediaemailsadvanced::ordered_list_bullet_5}} 5 {{custommediaemailsadvanced::custom_icon_5}} {{custommediaemailsadvanced::custom_icon_5_self_hosted}} {{custommediaemailsadvanced::custom_icon_5_width}} #000000 {{custommediaemailsadvanced::center_icons_in_mobile}} {{custommediaemailsadvanced::ordered_list_bullet_td_custom_css}} {{custommediaemailsadvanced::ordered_list_bullet_span_custom_css}} {{custommediaemailsadvanced::body_2_copy}} {{custommediaemailsadvanced::body_2_td_custom_css}} {{custommediaemailsadvanced::body_2_span_custom_css}} {{custommediaemailsadvanced::closing_emphasis_copy}} {{custommediaemailsadvanced::closing_emphasis_link_text}} {{custommediaemailsadvanced::closing_emphasis_link_url}} {{custommediaemailsadvanced::closing_emphasis_link_color}} {{custommediaemailsadvanced::closing_emphasis_td_custom_css}} {{custommediaemailsadvanced::closing_emphasis_span_custom_css}} background-color: #4d4e4e; Learn how conditionally approved{br}drugs can benefit veterinary{br}patients without sacrificing{nbs}safety. {{custommediaemailsadvanced::cta_line_1_custom_text_color}} true {{custommediaemailsadvanced::cta_line_2}} {{custommediaemailsadvanced::cta_line_2_custom_text_color}} {{custommediaemailsadvanced::cta_line_2_link}} Read More Now #5c2e84 {{custommediaemailsadvanced::custom_button_text_color}} https://www.cliniciansbrief.com/article/fda-conditional-approval-what-does-it-mean-what-should-veterinarians-know {{custommediaemailsadvanced::footnote}} {{custommediaemailsadvanced::large_footnote_copy}} {{custommediaemailsadvanced::footnote_td_custom_css}} {{custommediaemailsadvanced::footnote_span_custom_css}} {{custommediaemailsadvanced::pre_footer_copy}} {{custommediaemailsadvanced::pre_footer_center}}
Conditionally Approved Drug for the Epileptic Patient
{{custommediaemailsadvanced::logo_alt_text}}
{{custommediaemailsadvanced::headline}}

Finding a safe and effective treatment protocol for dogs with seizures can often serve up a challenge for the veterinary practitioner. KBroVet®-CA1 is a conditionally approved, flavored, chewable tablet for the treatment of idiopathic epilepsy in dogs, with a proven safety record from the FDA. 

Learn how conditionally approved{br}drugs can benefit veterinary{br}patients without sacrificing{nbs}safety.
{{custommediaemailsadvanced::cta_line_2}}
Read More Now
{{custommediaemailsadvanced::logo_alt_text}}
</head> <body style="-ms-text-size-adjust:100%;-webkit-text-size-adjust:100%;margin:0;min-width:100%;padding:0;width:100%" data-bg-color="#e8e8e8" bgcolor="#e8e8e8">
Conditionally Approved Drug for the Epileptic Patient
{{custommediaemailsadvanced::logo_alt_text}}
{{custommediaemailsadvanced::headline}}

Finding a safe and effective treatment protocol for dogs with seizures can often serve up a challenge for the veterinary practitioner. KBroVet®-CA1 is a conditionally approved, flavored, chewable tablet for the treatment of idiopathic epilepsy in dogs, with a proven safety record from the FDA. 

Learn how conditionally approved{br}drugs can benefit veterinary{br}patients without sacrificing{nbs}safety.
{{custommediaemailsadvanced::cta_line_2}}
Read More Now
{{custommediaemailsadvanced::logo_alt_text}}